University of Michigan researchers have introduced MPS2, a urine-based test that identifies aggressive prostate cancers and reduces unnecessary biopsies, enhancing prostate cancer management.
The test, called MyProstateScore2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. In multiple tests using urine and tissue samples from men with prostate cancer, it successfully identified cancers classified as Gleason 3+4=7 or Grade Group 2 , or higher. These cancers are more likely to grow and spread compared to Gleason 6 or Grade Group 1 prostate cancers, which are unlikely to spread or cause other impact.
This first step narrowed the field to 18 markers that consistently correlated with higher grade disease. The test still includes the original MPS markers, plus 16 additional biomarkers to complement them.From there, the team reached out to the larger Early Detection Research Network , a consortium of more than 30 labs across the country that are similarly collecting samples. This ensured a diverse, national sampling.
“Four of 10 men who would have a negative biopsy will have a low risk MPS2 result and can confidently skip a biopsy. If a man has had a biopsy before, the test works even better,” Wei explained.
Source: Healthcare Press (healthcarepress.net)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: PhillyInquirer - 🏆 81. / 68 Read more »
Source: BestLifeOnline - 🏆 533. / 51 Read more »
Source: screenrant - 🏆 7. / 94 Read more »
Source: PhoneArena - 🏆 322. / 59 Read more »
Source: CNBC - 🏆 12. / 72 Read more »